On Wednesday, Shares of United States Steel Corporation (NYSE:X), lost -4.20% to $19.15.
United States Steel Corporation, declared that interested stockholders, investors and others may listen to the company’s second quarter 2015 conference call with securities analysts on Wednesday, July 29, 2015, at 8:30 a.m. EDT. The call, which will be accessible via the U. S. Steel website, will cover second quarter 2015 financial results and may comprise forward-looking information. The company plans to release its second quarter 2015 financial results following the close of trading on the New York Stock Exchange on Tuesday, July 28.
U. S. Steel officials participating in the call will be Mario Longhi, president and CEO; David B. Burritt, executive vice president and CFO; and Dan Lesnak, general manager-investor relations.
United States Steel Corporation produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments: Flat-Rolled Products (Flat-Rolled), U. S. Steel Europe (USSE), and Tubular Products (Tubular).
Shares of Intersil Corp (NASDAQ:ISIL), inclined 0.33% to $12.05, during its last trading session.
Intersil Corp, declared the appointment of Ernest Maddock to its board of directors. Mr. Maddock’s 35 plus years of experience comprises senior leadership roles in finance, operations, and general administration. He is presently the chief financial officer at Micron, a multi-billion dollar semiconductor company with a market-leading portfolio of memory solutions.
“We are happy to add another practiced technology executive to our board of directors,” said Don Macleod, chairman of Intersil’s board. “We believe Ernie’s deep finance and operational background complements the expertise of our existing board members.”
Intersil Corporation designs and develops power administration and precision analog integrated circuits (ICs) for industrial and infrastructure, consumer, and computing markets.
Finally, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ended its last trade with -5.44% loss, and closed at $11.65.
Vanda Pharmaceuticals, declared that a HETLIOZ patent, number 9,060,995 (‘995 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The ‘995 patent was issued by the United States Patent and Trademark Office on June 23rd, 2015 and expires in January 2033. Preceding to this newly listed ‘995 patent, the HETLIOZ Orange Book listed patents were the U.S. composition of matter ‘529 patent and the ‘492 patent, predictable to expire in December 2022 (assuming receipt of the five year patent term extension under the Hatch-Waxman Act) and January 2033, respectively.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products comprise HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
